Drug Discovery World

AUGUST 21, 2023

However, because these cancers are not driven by any of the three molecules that can be blocked by targeted hormone receptor drugs, current treatment options are limited. After 30 minutes of therapy, the mean capture efficiencies for sTNF-R1 and sTNF-R2 – the proteins shed by tumours that suppress endogenous TNF-α – were 95.2%

Protein 52

Protein Trials Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. The partial piece of the spike protein cannot cause COVID-19 disease.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

The Pharma Data

JANUARY 4, 2021

CITYSCAPE provides the first evidence that targeting both immune inhibitory receptors, TIGIT and PD-L1, may enhance anti-tumor activity by potentially amplifying the immune response. “We TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. Dual blockade of the TIGIT and PD-L1 pathways.

Immune Response 52

Immune Response Medicine Protein Gene 52

The Pharma Data

JANUARY 21, 2021

Researchers at Stanford Medicine , investigating old mice and human cell cultures, found that immune cells called myeloid cells, which are found in the brain, circulatory system and peripheral tissues not only battle infectious agents, but work on cleaning up debris, like dead cells and aggregated proteins.

Research 52

Research DNA Hormones Vaccination 52

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Trials 40

Trials DNA Medicine Development 40

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52